Risankizumab Safe, Effective at 52 Weeks for Psoriatic Arthritis

WEDNESDAY, Jan. 11, 2023 -- Risankizumab provides long-term benefits in patients with psoriatic arthritis (PsA) who have not achieved adequate response to previous therapies, according to a study recently published in Rheumatology.
Andrew Östör,...